Cover ImageSALE
市場調查報告書

全球新興癌症診斷 (腫瘤生物標記檢驗) 市場分析與預測:生物標記檢驗類型,應用,市場趨勢

Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2016-2023: Focus on Biomarker Test Type, Application & Market Trends

出版商 BIS Research 商品編碼 482398
出版日期 內容資訊 英文 341 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球新興癌症診斷 (腫瘤生物標記檢驗) 市場分析與預測:生物標記檢驗類型,應用,市場趨勢 Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market Analysis & Forecast 2016-2023: Focus on Biomarker Test Type, Application & Market Trends
出版日期: 2017年03月27日 內容資訊: 英文 341 Pages
簡介

本報告提供全球新興癌症診斷市場相關調查分析,提供您市場動態,競爭情形,各市場區隔的市場分析,各地區分析,主要企業等系統性資訊。

第1章 調查範圍·手法

第2章 簡介

第3章 市場動態

  • 推動市場要素
  • 市場課題
  • 市場機會

第4章 競爭分析

  • 市場發展與策略
  • 產業的魅力
  • 全球市場佔有率分析

第5章 產業分析

  • 專利分析
  • 相關團體,法規當局

第6章 全球新興癌症診斷市場分析與預測

  • 前提條件與限制
  • 市場概要
  • 腫瘤生物標記檢查別
  • 各應用
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 其他

第7章 企業簡介

  • Abbott Laboratories, Inc.
  • Agilent Technologies
  • AstraZeneca
  • Becton Dickinson & Co.
  • Biocept Inc.
  • Cancer Genetics Inc.
  • Danaher Corporation
  • Foundation Medicine Inc.
  • Illumina Inc.
  • LabCorp Of America Holdings
  • Luminex Corporation
  • Myriad Genetics Inc.
  • NanoString Technologies Inc.
  • Neo Genomics Inc.
  • Quest Diagnostics Incorporated
  • Qiagen, Inc.
  • Roche Holding AG-BR
  • Siemens Healthineers
  • Thermo Fisher Scientific
  • 其他
目錄
Product Code: BH013A

The global emerging cancer diagnostics market is expected to grow at a CAGR of 13.45% from 2016 to 2023 and reach a figure of $6.34 billion by 2023. The advancements in technology, adoption of biomarker tests, and increasing cancer incidence rate are some of the major driving factors for this market. The global emerging cancer diagnostics market has been classified on the basis of test type, application and geography.

Cancer is a chronic disease and is affecting a huge population. Many technologies are emerging in the cancer diagnostics market. This report is focused on emerging cancer diagnostics market specifically on biomarker tumor test. The market growth is propelled due to factors such as: increasing number of cancer cases, technological innovation and advancements, increasing awareness among people, and medicare & reimbursement policies, among others.

This study includes an overview and analysis of the emerging cancer diagnostics market, by test type, applications, and geography, allowing the research to develop a comprehensive outlook of the market. The market report presents a detailed and analytical study of the entire market and provides a comprehensive insight into various forms of developments, trends and key participants. The type of cancer, their incidence and prevalence rate has been discussed in the report. All of the above mentioned report coverage parameters are discussed across different regions such as North America, Europe, Asia Pacific (APAC), and Rest of the World (ROW).

While highlighting the key driving and restraining forces for this dynamic market, the report also provides a comprehensive section of the prominent consortiums, associations, and regulatory bodies, and their involvement in the emerging cancer diagnostics market.

The answers to the following key questions can be found in the report:

  • What are the major drivers, challenges and opportunities of the tumor biomarker test market and their use cases?
  • How is the tumor biomarker test market evolving?
  • What are the market shares of the leading segments of the tumor biomarker test market in 2015?
  • How will each test of the tumor biomarker test grow over the forecast period and how much revenue will these account for in 2023?
  • How will the market shares of the leading national markets change by 2023 and which country will lead the market in 2023?
  • How the industry will evolve during the forecast period between 2016 and 2023?
  • What are the key developmental strategies implemented in different applications across all regions?
  • How will the key market players leverage on key developments such as mergers & acquisitions, partnerships, and product launches among others?
  • Which geographical region will lead the global tumor biomarker test market by the end of the forecast period?
  • Who are the key players in the tumor biomarker test market?
  • What are different application in this market and how are they categorized?
  • What are the market trends and key developments in different geographical regions?
  • What are all market available cancer biomarker test?
  • What is the current market size and future projection for emerging cancer technologies in the major countries?
  • What are the key sources of information about emerging cancer technologies?
  • What is the incidence rate of major cancer type?

The research study tries to answer various aspects of the emerging cancer diagnostics market with the help of central factors driving the market, threats that can possibly slow down the overall market growth, and the current growth opportunities that are going to shape the future trajectory of the market expansion. The study takes into account Porter's Five Force model and opportunity matrix for an in-depth study of the emerging cancer diagnostics market and an assessment of the factors governing the same.

Table of Contents

Executive Summary

1. T he Research Scope and Methodology

  • 1.1. Scope of the Report
  • 1.2. Global Emerging Cancer Diagnostics Market Research Methodology

2. I ntroduction to Global Emerging Cancer Diagnostics Market

  • 2.1. Overview
  • 2.2. Analysis of Lifestyle Factors
    • 2.2.1. Obesity/Weight
    • 2.2.2. Physical Activity
    • 2.2.3. Food Habits
    • 2.2.4. Alcohol & Cancer
      • 2.2.4.1. Countries with Highest Consumption Of Alcoholic Drinks
    • 2.2.5. Salt Consumption
    • 2.2.6. Breastfeeding
  • 2.3. High and Low Developed Countries
    • 2.3.1. Men
    • 2.3.2. Women
  • 2.4. Data for Cancer Frequency By Country
    • 2.4.1. Men
    • 2.4.2. Women
  • 2.5. Worldwide Cancer Data
    • 2.5.1. Men
    • 2.5.2. Women

3. M arket Dynamics

  • 3.1. Market Drivers
    • 3.1.1. Increase in Prevalence Rate Of Cancer
    • 3.1.2. Increase in Sedentary Lifestyles
    • 3.1.3. Robust Technological Advancement
    • 3.1.4. Environmental Hazards
      • 3.1.4.1. Five primary categories of carcinogens are: -
    • 3.1.5. Government Initiatives and Investment
  • 3.2. Market Challenges
    • 3.2.1. High Capital Investment
    • 3.2.2. Dearth of Skilled Professionals
    • 3.2.3. Lack of Awareness
  • 3.3. Market Opportunities
    • 3.3.1. Nanotechnology Applications In Cancer
    • 3.3.2. 3D Printing In Cancer Diagnostics
    • 3.3.3. Robotics In Cancer Diagnostics And Treatment
    • 3.3.4. Fluid Biopsy
    • 3.3.5. Real Time Cancer Diagnostic iKnife

4. Competitive Insights

  • 4.1. Key Market Developments & Strategies
    • 4.1.1. Product Launch and Development
    • 4.1.2. Collaborations, Joint Ventures & Partnerships
    • 4.1.3. Business Expansion and Contracts
    • 4.1.4. Patents, Approvals and Certifications
    • 4.1.5. Mergers and Acquisitions
    • 4.1.6. Other Strategies
  • 4.2. Industry Attractiveness
  • 4.3. Global Market Share Analysis
    • 4.3.1. Market Share Analysis

5. I ndustry Analysis

  • 5.1. Patent Analysis
  • 5.2. Consortiums, Associations and Regulatory Bodies

6. Global Emerging Cancer Diagnostics (Tumor Biomarker Test) Market, Analysis and Forecast

  • 6.1. Assumptions & Limitations for Analysis and Forecast
  • 6.2. Market Overview
  • 6.3. Global Emerging Cancer Diagnostics Market by Tumor Biomarker Test
    • 6.3.1. Prostate Specific Antigen Tests
    • 6.3.2. CTC Tests
    • 6.3.3. Alpha-Fetoprotein (AFP) Tests
    • 6.3.4. CA Test
      • 6.3.4.1. CA 19-9 Tests
      • 6.3.4.2. CA 125 Tests
    • 6.3.5. HER2 Tests
    • 6.3.6. BRCA Test
    • 6.3.7. Anaplastic Lymphoma Kinase (ALK) Tests
    • 6.3.8. EGFR Mutation Tests
    • 6.3.9. KRAS Test
    • 6.3.10. Others
      • 6.3.10.1. National Rental Affordability Scheme (NRAS) Testing
      • 6.3.10.2. RET Gene Testing
      • 6.3.10.3. ROS Testing
      • 6.3.10.4. PIK3CA Tests
  • 6.4. Global Emerging Cancer Diagnostics Market by Application
    • 6.4.1. Lung cancer
    • 6.4.2. Breast cancer
    • 6.4.3. Colorectal
    • 6.4.4. Prostate Cancer
    • 6.4.5. Blood Cancer
      • 6.4.5.1. Leukaemia
      • 6.4.5.2. Lymphoma
      • 6.4.5.3. Myeloma
    • 6.4.6. Others
  • 6.5. Global Emerging Technologies in Cancer Diagnostics Market by Geography
    • 6.5.1. North America
      • 6.5.1.1. Country Analysis
        • 6.5.1.1.1. U.S.
        • 6.5.1.1.2. Canada
    • 6.5.2. Europe
      • 6.5.2.1. Countries having the highest cancer rates
      • 6.5.2.2. Germany
      • 6.5.2.3. France
      • 6.5.2.4. The U.K.
      • 6.5.2.5. Denmark
      • 6.5.2.6. Belgium
      • 6.5.2.7. Norway
    • 6.5.3. APAC
      • 6.5.3.1. India
      • 6.5.3.2. China
      • 6.5.3.3. Japan
      • 6.5.3.4. Australia
      • 6.5.3.5. Singapore
      • 6.5.3.6. Others APAC Region
    • 6.5.4. Rest of the World
      • 6.5.4.1. Middle East
      • 6.5.4.2. Africa
      • 6.5.4.3. South America

7. Company Profiles

  • 7.1. Abbott Laboratories, Inc.
    • 7.1.1. Overview
    • 7.1.2. Financials
      • 7.1.2.1. Financial Summary
    • 7.1.3. SWOT Analysis
  • 7.2. Agilent Technologies
    • 7.2.1. Overview
    • 7.2.2. Financials
      • 7.2.2.1. Financial Summary
    • 7.2.3. SWOT Analysis
  • 7.3. AstraZeneca
    • 7.3.1. Overview
    • 7.3.2. Financials
      • 7.3.2.1. Financial Summary
    • 7.3.3. SWOT Analysis
  • 7.4. Becton Dickinson & Co.
    • 7.4.1. Overview
    • 7.4.2. Financials
      • 7.4.2.1. Financial Summary
    • 7.4.3. SWOT Analysis
  • 7.5. Biocept Inc.
    • 7.5.1. Overview
    • 7.5.2. Financials
      • 7.5.2.1. Financial Summary
    • 7.5.3. SWOT Analysis
  • 7.6. Cancer Genetics Inc.
    • 7.6.1. Overview
    • 7.6.2. Financials
      • 7.6.2.1. Financial Summary
    • 7.6.3. SWOT Analysis
  • 7.7. Danaher Corporation
    • 7.7.1. Overview
    • 7.7.2. Financials
      • 7.7.2.1. Financial Summary
    • 7.7.3. SWOT Analysis
  • 7.8. Foundation Medicine Inc.
    • 7.8.1. Overview
    • 7.8.2. Financials
    • 7.8.3. SWOT Analysis
  • 7.9. Illumina Inc.
    • 7.9.1. Overview
    • 7.9.2. Financials
    • 7.9.3. Financial Summary
    • 7.9.4. SWOT Analysis
  • 7.10. LabCorp Of America Holdings
    • 7.10.1. Overview
    • 7.10.2. Financials
      • 7.10.2.1. Financial Summary
    • 7.10.3. SWOT Analysis
  • 7.11. Luminex Corporation
    • 7.11.1. Overview
    • 7.11.2. Financials
      • 7.11.2.1. Financial Summary
    • 7.11.3. SWOT Analysis
  • 7.12. Myriad Genetics Inc.
    • 7.12.1. Overview
    • 7.12.2. Financials
      • 7.12.2.1. Financial Summary
    • 7.12.3. SWOT Analysis
  • 7.13. NanoString Technologies Inc.
    • 7.13.1. Overview
    • 7.13.2. Financials
      • 7.13.2.1. Financial Summary
    • 7.13.3. SWOT Analysis
  • 7.14. Neo Genomics Inc.
    • 7.14.1. Overview
    • 7.14.2. Financials
      • 7.14.2.1. Financial Summary
    • 7.14.1. SWOT Analysis
  • 7.15. Quest Diagnostics Incorporated
    • 7.15.1. Overview
    • 7.15.2. Financials
      • 7.15.2.1. Financial Summary
    • 7.15.3. SWOT Analysis
  • 7.16. Qiagen, Inc.
    • 7.16.1. Overview
    • 7.16.2. Financials
    • 7.16.3. Financial Summary
    • 7.16.4. SWOT Analysis
  • 7.17. Roche Holding AG-BR
    • 7.17.1. Overview
    • 7.17.2. Financials
    • 7.17.3. Financial Summary
    • 7.17.4. SWOT Analysis
  • 7.18. Siemens Healthineers
    • 7.18.1. Overview
    • 7.18.2. Financials
      • 7.18.2.1. Financial Summary
    • 7.18.3. SWOT Analysis
  • 7.19. Thermo Fisher Scientific
    • 7.19.1. Overview
    • 7.19.2. Financials
      • 7.19.2.1. Financial Summary
    • 7.19.3. SWOT Analysis
  • 7.20. Snapshot of Other Key Players
    • 7.20.1. Biotheranostics, Inc.
    • 7.20.2. Epigenomics
    • 7.20.3. Exact Sciences Corporation
    • 7.20.4. Ignyta,Inc.
    • 7.20.5. Interpace Diagnostics
    • 7.20.6. Leica Biosystems
    • 7.20.7. BioTime, Inc
    • 7.20.8. Pathway Genomics
    • 7.20.9. Sysmex Corporation
    • 7.20.10. Almac group
    • 7.20.11. GeneNews Limited (formerly ChondroGene Limited)
    • 7.20.12. Rosetta Genomics
Back to Top